Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront

被引：4
|
作者：
Breccia, Massimo [1 ]
Molica, Matteo [1 ]
Colafigli, Gioia [1 ]
Zacheo, Irene [1 ]
Latagliata, Roberto [1 ]
Tafuri, Agostino [2 ,3 ]
Alimena, Giuliana [1 ]
机构：
[1] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, I-00161 Rome, Italy
[2] S Andrea Hosp, Hematol, Rome, Italy
[3] Univ Roma La Sapienza, Dept Mol Med, Hematol, I-00161 Rome, Italy
来源：
LEUKEMIA & LYMPHOMA | 2015年 / 56卷 / 07期
关键词：
D O I：
10.3109/10428194.2014.993391
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2206 / 2207
页数：2
相关论文
共 50 条
  • [31] Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia
    Kantarjian, Hagop M.
    Jabbour, Elias
    Deininger, Michael
    Abruzzese, Elisabetta
    Apperley, Jane
    Cortes, Jorge
    Chuah, Charles
    DeAngelo, Daniel J.
    DiPersio, John
    Hochhaus, Andreas
    Lipton, Jeffrey
    Nicolini, Franck E.
    Pinilla-Ibarz, Javier
    Rea, Delphine
    Rosti, Gianantonio
    Rousselot, Philippe
    Shah, Neil P.
    Talpaz, Moshe
    Srivastava, Shouryadeep
    Ren, Xiaowei
    Mauro, Michael
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (11) : 1419 - 1426
  • [32] CLINICAL SIGNIFICANCE OF EARLY MOLECULAR RESPONSES IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH FIRST-LINE SECOND-GENERATION TYROSINE KINASE INHIBITORS
    Lee, S.
    Choi, S.
    Kim, S.
    Bang, J.
    Oh, Y.
    Park, J.
    Jeon, H.
    Jang, E.
    Kim, D.
    HAEMATOLOGICA, 2013, 98 : 51 - 52
  • [33] Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia Treated with First- Versus Second-Generation Tyrosine Kinase Inhibitors
    Shacham Abulafia, Adi
    Shemesh, Sivan
    Rosenmann, Lena
    Berger, Tamar
    Leader, Avi
    Sharf, Giora
    Raanani, Pia
    Rozovski, Uri
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11) : 1 - 9
  • [34] Sustained complete molecular response of chronic myeloid leukemia after discontinuation of second-generation tyrosine kinase inhibitors
    Aoki, Jun
    Ohashi, Kazuteru
    Kobayashi, Takeshi
    Kakihana, Kazuhiko
    Hirashima, Yuka
    Sakamaki, Hisashi
    LEUKEMIA & LYMPHOMA, 2012, 53 (07) : 1412 - 1414
  • [35] Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia
    Delgado, Livia
    Giraudier, Stephane
    Ortonne, Nicolas
    Zehou, Ouidad
    Cordonnier, Catherine
    Hulin, Anne
    Chosidow, Olivier
    Tulliez, Michel
    Valeyrie-Allanore, Laurence
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 69 (05) : 839 - 840
  • [36] Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors
    Hochhaus, Andreas
    Breccia, Massimo
    Saglio, Giuseppe
    Garcia-Gutierrez, Valentin
    Rea, Delphine
    Janssen, Jeroen
    Apperley, Jane
    LEUKEMIA, 2020, 34 (06) : 1495 - 1502
  • [37] Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia
    Fujiwara, Shin-ichiro
    Shirato, Yuya
    Ikeda, Takashi
    Kawaguchi, Shin-ichiro
    Toda, Yumiko
    Ito, Shoko
    Ochi, Shin-ichi
    Nagayama, Takashi
    Mashima, Kiyomi
    Umino, Kento
    Minakata, Daisuke
    Nakano, Hirofumi
    Morita, Kaoru
    Yamasaki, Ryoko
    Kawasaki, Yasufumi
    Sugimoto, Miyuki
    Ashizawa, Masahiro
    Yamamoto, Chihiro
    Hatano, Kaoru
    Sato, Kazuya
    Oh, Iekuni
    Ohmine, Ken
    Muroi, Kazuo
    Kanda, Yoshinobu
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 107 (06) : 712 - 715
  • [38] Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia
    Shin-ichiro Fujiwara
    Yuya Shirato
    Takashi Ikeda
    Shin-ichiro Kawaguchi
    Yumiko Toda
    Shoko Ito
    Shin-ichi Ochi
    Takashi Nagayama
    Kiyomi Mashima
    Kento Umino
    Daisuke Minakata
    Hirofumi Nakano
    Kaoru Morita
    Ryoko Yamasaki
    Yasufumi Kawasaki
    Miyuki Sugimoto
    Masahiro Ashizawa
    Chihiro Yamamoto
    Kaoru Hatano
    Kazuya Sato
    Iekuni Oh
    Ken Ohmine
    Kazuo Muroi
    Yoshinobu Kanda
    International Journal of Hematology, 2018, 107 : 712 - 715
  • [39] A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors
    Zulbaran-Rojas, Alejandro
    Lin, Huei-Kan
    Shi, Qiuling
    Williams, Loretta A.
    George, Binsah
    Garcia-Manero, Guillermo
    Jabbour, Elias
    O'Brien, Susan
    Ravandi, Farhad
    Wierda, William
    Estrov, Zeev
    Borthakur, Gautam
    Kadia, Tapan
    Cleeland, Charles
    Cortes, Jorge E.
    Kantarjian, Hagop
    CANCER MEDICINE, 2018, 7 (11): : 5457 - 5469
  • [40] Acneiform eruptions caused by various second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia
    Jung, Y. S.
    Kim, M.
    Lee, J. H.
    Kim, D. W.
    Park, H. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 174 (02) : 456 - 458
12345